Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

The IMpower-132 trial for non small cell lung cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.10.18
Views: 983

Dr Vassiliki Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, US

Dr Vassiliki Papadimitrakopoulou speaks with ecancer at ESMO 2018 in Munich about her abstract for metastatic NSCLC regarding the IMpower-132 trial.

She gives a brief outline of the trial design and preliminary results, as well as information about subgroup analyses from the study.

These results are also discussed by Dr Fabrice Barlesi, here.

ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation